Sionna Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Viking Global Investors filed an amended Schedule 13G to reflect the retirement of David C. Ott from its reporting group.
NASDAQ
Qatar Investment Authority and its subsidiary Q Healthcare Holding LLC have reported beneficial ownership of 4.5% of Sionna Therapeutics Inc. common stock as of March 31, 2026.
NASDAQ
JPMorgan Chase & Co. has filed an amendment to its Schedule 13G, disclosing a 4.4% beneficial ownership stake in Sionna Therapeutics, Inc.
NASDAQ
JPMorgan Chase & Co. has reported a 5.0% beneficial ownership stake in Sionna Therapeutics, Inc., holding 2,221,188 shares of common stock.
NASDAQ
Qatar Investment Authority and its affiliate, Q Healthcare Holding LLC, have disclosed a 5.0% beneficial ownership stake in Sionna Therapeutics Inc, holding 2,209,775 shares of Common Stock.
NASDAQ
Viking Global Investors LP and its affiliates have reported a beneficial ownership of 6.7% in Sionna Therapeutics, Inc. common stock, totaling 2,952,754 shares, following the company's recent initial public offering.